Fig. 3
From: Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis
CL27c decreases leukocyte infiltration into the lungs and production of inflammatory markers in OVA-induced chronic allergic asthma model. a Protocol of OVA-induced chronic allergic asthma and daily treatment regimen with aerosolized CL27c (2 mg/ml) or Dexamethasone (Dexa, 5 mg/kg, i.e.; positive control). b Quantification of infiltrating macrophages, neutrophils, eosinophils, and lymphocytes in BALF after treatment with either CL27c or Dexamethasone (Dexa) (from left to right, macropages n = 7, 8, 7, 7, neutrophils n = 5, 8, 7, 7, eosinophils n = 5, 8, 7, 7, and lymphocytes n = 5, 8, 6, 7 independent experiments, respectively). c Measurement of the accumulation of neutrophil myeloperoxidase (MPO) and eosinophil peroxidase (EPO) in lung tissues after treatment with either CL27c or Dexamethasone (from left to right, EPO n = 5, 7, 7, 8 and MPO n = 5, 7, 6, 5 independent experiments, respectively). d Quantification of inflammatory cytokines (IL-5 and IL-13) and of the chemokine eotaxin after treatment with either CL27c or Dexamethasone (from left to right, IL-5 n = 5, 5, 6, 6, IL-13 n = 8, 6, 6, 6, Eotaxin n = 5, 5, 4, 5 independent experiments, respectively). Results represent mean ± s.e.m., *P < 0.05, **P < 0.01, ***P < 0.001 determined using one-way ANOVA followed by Bonferroni post-hoc test
